DoseMe Acquires Firstline to Create Integrated Clinical Decision Support Platform for Antimicrobial Stewardship
核心洞察
DoseMe (搜索), a global leader in model-informed precision dosing software, has acquired Firstline (搜索), a clinical decision support platform, to create an end-to-end solution for antimicrobial stewardship.
The combined platform addresses the growing challenge of antibiotic resistance (搜索), which costs the U.S. healthcare system $21-34 billion annually and results in over 8 million excess hospital days.
The integration bridges the gap between antimicrobial stewardship policy and practice, enabling clinicians to move seamlessly from evidence-based treatment selection to individualized precision dosing.
DoseMe (搜索), a global leader in model-informed precision dosing (MIPD) software and portfolio company of Fairlong Capital (搜索), has announced the acquisition of Firstline (搜索), a leading clinical decision support platform used by clinicians worldwide. The transaction creates an integrated solution that enables healthcare providers to move seamlessly from evidence-based treatment selection to individualized precision dosing, addressing the critical challenge of antimicrobial resistance.
Addressing the Growing Burden of Antibiotic Resistance
The merger responds to the escalating global challenge of antibiotic resistance (搜索), which imposes a substantial economic burden on healthcare systems. According to the companies, antibiotic-resistant infections (搜索) cost the U.S. healthcare system between $21 billion and $34 billion annually and result in more than 8 million excess hospital days.
"Firstline (搜索) is the perfect complement to DoseMe (搜索) with proven value that provides impact on patient outcomes, hospital ecology, and combating antimicrobial resistance," said Paul Edwards, CEO of DoseMe. "Together, we support AMS initiatives and speed up optimized patient care decisions by helping clinicians access local stewardship protocols and translate them directly into personalized precision dosing."
Complementary Technologies Create Unified Platform
The acquisition brings together two innovative healthcare technology platforms with distinct but complementary capabilities. Firstline (搜索)'s platform provides clinicians with rapid access to local treatment protocols for contagious diseases, susceptibility data, and stewardship resources. Meanwhile, DoseMe (搜索)'s technology enables clinicians to calculate personalized dosing in seconds, based on patient characteristics and pharmacokinetic models.
The combined organization, headquartered in Jupiter, Florida, and Vancouver, British Columbia, aims to strengthen the global fight against infectious disease (搜索) by improving antimicrobial stewardship (AMS), advancing patient outcomes, and reducing healthcare costs.
Global Impact and Clinical Applications
Firstline (搜索) has established itself as a trusted platform among leading healthcare organizations worldwide, delivering clinical guidance to hospitals, governments, and the World Health Organization. The platform is designed to reduce antibiotic overuse, improve adherence to stewardship guidance, and provide clinicians with fast, reliable access to local resistance data.
"We're immensely proud to have built Firstline (搜索) into an organization delivering clinical guidance globally to hospitals, governments and the World Health Organization," said Dr. Michael Long, co-founder and Chief Clinical Officer of Firstline. "We're excited to see Firstline continue to flourish as part of the larger DoseMe (搜索) organization."
Technology Integration and Clinical Value
DoseMe (搜索)'s platform combines smart technology with science, leveraging clinically-validated PK/PD models, patient characteristics, drug concentrations, and genotype to accurately individualize doses in seconds. The platform maintains HIPAA compliance and holds both HITRUST CSF R2 and ISO 13485 certifications, making it the only Bayesian dosing platform with these dual certifications.
The integration creates a single connected platform that bridges the gap between AMS policy and practice, allowing hospitals, governments, and healthcare organizations worldwide to accelerate precision care. The unified solution converts stewardship policy into real-time, actionable intelligence at the point of care.
Strategic Investment and Future Outlook
Fairlong Capital (搜索), which backs DoseMe (搜索), views the acquisition as enhancing the company's ability to deliver personalized medicine solutions that drive both clinical and economic value. "The combination of DoseMe and Firstline (搜索) advances the mission to address the full patient care continuum of personalized medicine," said David Neiman, Managing Partner at Fairlong Capital. "We look forward to the consolidated business' continued growth, but most importantly to the profound impact this combination will have on the customer's ability to improve patient care."